Sensitivity of the Predictive Hypoglycemia Minimizer System to the Algorithm Aggressiveness Factor

Background: The Predictive Hypoglycemia Minimizer System (“Hypo Minimizer”), consisting of a zone model predictive controller (the “controller”) and a safety supervision module (the “safety module”), aims to mitigate hypoglycemia by preemptively modulating insulin delivery based on continuous glucose monitor (CGM) measurements. The “aggressiveness factor,” a pivotal variable in the system, governs the speed and magnitude of the controller’s insulin dosing characteristics in response to changes in CGM levels. Methods: Twelve adults with type 1 diabetes were studied in closed-loop in a clinical research center for approximately 24 hours. This analysis focused primarily on the effect of the aggressiveness factor on the automated insulin-delivery characteristics of the controller, and secondarily on the glucose control results. Results: As aggressiveness increased from “conservative” to “medium” to “aggressive,” the controller recommended less insulin (–3.3% vs –14.4% vs –19.5% relative to basal) with a higher frequency (5.3% vs 14.4% vs 20.3%) during the critical times when the CGM was reading 90-120 mg/dl and decreasing. Blood glucose analyses indicated that the most aggressive setting resulted in the most desirable combination of the least time spent <70 mg/dl and the most time spent 70-180 mg/dl, particularly in the overnight period. Hyperglycemia, diabetic ketoacidosis, or severe hypoglycemia did not occur with any of the aggressiveness values. Conclusion: The Hypo Minimizer’s controller took preemptive action to prevent hypoglycemia based on predicted changes in CGM glucose levels. The most aggressive setting was quickest to take action to reduce insulin delivery below basal and achieved the best glucose metrics.

[1]  Eyal Dassau,et al.  Modular Artificial β-Cell System: A Prototype for Clinical Research , 2008 .

[2]  Niels Kjølstad Poulsen,et al.  Model-Based Closed-Loop Glucose Control in Type 1 Diabetes: The DiaCon Experience , 2013, Journal of diabetes science and technology.

[3]  Roman Hovorka,et al.  Day and Night Home Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes: Three-Center Randomized Crossover Study , 2014, Diabetes Care.

[4]  Roman Hovorka,et al.  Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. , 2014, The lancet. Diabetes & endocrinology.

[5]  Marc D. Breton,et al.  Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp , 2014, Diabetes Care.

[6]  Eyal Dassau,et al.  Closed-Loop Control Performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System in a Feasibility Study , 2014, Journal of diabetes science and technology.

[7]  L. Magni,et al.  First Use of Model Predictive Control in Outpatient Wearable Artificial Pancreas , 2014, Diabetes Care.

[8]  Howard C. Zisser,et al.  Clinical Evaluation of a Personalized Artificial Pancreas , 2013, Diabetes Care.

[9]  Marc D. Breton,et al.  Modular Closed-Loop Control of Diabetes , 2012, IEEE Transactions on Biomedical Engineering.

[10]  Roman Hovorka,et al.  Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents , 2014, BMJ Open Diabetes Research and Care.

[11]  Howard C. Zisser,et al.  Feasibility of Outpatient Fully Integrated Closed-Loop Control , 2013, Diabetes Care.

[12]  Marc D. Breton,et al.  Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas , 2014, Diabetes Care.

[13]  Stephen D Patek,et al.  Hypoglycemia Prevention via Pump Attenuation and Red-Yellow-Green “Traffic” Lights Using Continuous Glucose Monitoring and Insulin Pump Data , 2010, Journal of diabetes science and technology.

[14]  David M Nathan,et al.  Outpatient glycemic control with a bionic pancreas in type 1 diabetes. , 2014, The New England journal of medicine.

[15]  David M Nathan,et al.  Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. , 2014, The Journal of clinical endocrinology and metabolism.

[16]  Aaron J. Kowalski,et al.  Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. , 2009, Diabetes technology & therapeutics.

[17]  W. Kenneth Ward,et al.  Automated Control of an Adaptive Bihormonal, Dual-Sensor Artificial Pancreas and Evaluation During Inpatient Studies , 2014, IEEE Transactions on Biomedical Engineering.

[18]  E. Atlas,et al.  Nocturnal glucose control with an artificial pancreas at a diabetes camp. , 2013, The New England journal of medicine.

[19]  Lauren M. Huyett,et al.  Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms , 2014, Diabetes Care.

[20]  Howard C. Zisser,et al.  Fully Integrated Artificial Pancreas in Type 1 Diabetes , 2012, Diabetes.

[21]  Malgorzata E. Wilinska,et al.  Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial , 2014, Diabetes Care.

[22]  Marc D. Breton,et al.  Effect of Algorithm Aggressiveness on the Performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System , 2014, Journal of diabetes science and technology.